Intestinal pseudo-obstruction is a condition characterized by impairment of the muscle contractions that move food through the digestive tract. It can occur at any time of life, and its symptoms range from mild to severe. The condition may arise from abnormalities of the gastrointestinal muscles themselves (myogenic) or from problems with the nerves that control the muscle contractions (neurogenic).

Intestinal pseudo-obstruction leads to a buildup of partially digested food in the intestines. This buildup can cause abdominal swelling (distention) and pain, nausea, vomiting, and constipation or diarrhea. Affected individuals experience loss of appetite and impaired ability to absorb nutrients, which may lead to malnutrition. These symptoms resemble those of an intestinal blockage (obstruction), but in intestinal pseudo-obstruction no blockage is found.

Depending on the cause of intestinal pseudo-obstruction, affected individuals can have additional signs and symptoms. Some people with intestinal pseudo-obstruction have bladder dysfunction such as an inability to pass urine. Other features may include decreased muscle tone (hypotonia) or stiffness (spasticity) of the torso and limbs, weakness in the muscles that control eye movement (ophthalmoplegia), intellectual disability, seizures, unusual facial features, or recurrent infections.

When intestinal pseudo-obstruction occurs by itself, it is called primary or idiopathic intestinal pseudo-obstruction. The disorder can also develop as a complication of another health problem; in these cases, it is called secondary intestinal pseudo-obstruction. The condition can be episodic (acute) or persistent (chronic).

Frequency

The overall prevalence of intestinal pseudo-obstruction is unknown. Researchers in Japan have estimated the prevalence of chronic intestinal pseudo-obstruction in that country as 9 cases per million people.

Causes

In some individuals with primary intestinal pseudo-obstruction, the condition is caused by genetic changes affecting the FLNA or ACTG2 gene.

The protein produced from the FLNA gene, filamin A, attaches (binds) to proteins called actins and helps them form the branching network of filaments that make up the cytoskeleton, which gives structure to cells and allows them to change shape and move. FLNA gene mutations that cause intestinal pseudo-obstruction are thought to reduce levels of the filamin A protein or impair its function. Research suggests that decreased filamin A function may affect the shape of cells in the smooth muscles of
the gastrointestinal tract during development before birth, causing abnormalities in
the layering of these muscles. Smooth muscles line the internal organs; they contract
and relax without being consciously controlled. In the gastrointestinal tract, abnormal
layering of these muscles interferes with the ability to produce the coordinated waves of
contractions (peristalsis) that move food along during digestion.

Deletions or duplications of genetic material can affect all or part of the \textit{FLNA} gene, and
may also include adjacent genes on the X chromosome. Changes in adjacent genes
may account for some of the other signs and symptoms that can occur with intestinal
pseudo-obstruction.

The \textit{ACTG2} gene provides instructions for making a member of the actin family called
gamma (\(\gamma\))-2 actin. The \(\gamma\)-2 actin protein is found in smooth muscle cells of the intestinal
and urinary tracts. It is necessary for contraction of the smooth muscles in the intestines
and bladder. These contractions move food through the intestines as part of the
digestive process and empty urine from the bladder. \textit{ACTG2} gene mutations hinder
the formation of actin filaments in the cytoskeleton and reduce the ability of smooth
muscles in the intestines and bladder to contract, leading to the signs and symptoms of
intestinal pseudo-obstruction.

Secondary intestinal pseudo-obstruction occurs as a complication of other disorders
that damage muscles or nerves in the intestinal tract, such as Parkinson disease, type
2 diabetes, various types of muscular dystrophy, or Kawasaki disease. Additionally,
the condition is a characteristic feature of certain inherited syndromes such as
megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS) or mitochondrial
neurogastrointestinal encephalopathy disease (MNGIE disease). Infections, surgery, or
certain drugs can also cause secondary intestinal pseudo-obstruction.

Mutations in other genes involved in smooth muscle contraction can also cause
intestinal pseudo-obstruction. Studies suggest that mutations in additional genes that
have not been identified can also result in this condition. In some affected individuals,
the cause of intestinal pseudo-obstruction is unknown.

\textbf{Inheritance Pattern}

Intestinal pseudo-obstruction is often not inherited, and most affected individuals do not
have a family history of the disorder. When it does run in families, it can have different
inheritance patterns.

Intestinal pseudo-obstruction caused by \textit{FLNA} gene mutations is inherited in an X-
linked recessive pattern. The \textit{FLNA} gene is located on the X chromosome, which is
one of the two sex chromosomes. In males (who have only one X chromosome), one
altered copy of the gene in each cell is sufficient to cause the condition. In females (who
have two X chromosomes), a mutation would have to occur in both copies of the gene
to cause the disorder. Because it is unlikely that females will have two altered copies
of this gene, males are affected by X-linked recessive disorders much more frequently
than females. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.

Intestinal pseudo-obstruction caused by ACTG2 gene mutations is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.

Some other cases of intestinal pseudo-obstruction are inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

- chronic idiopathic intestinal pseudo-obstruction
- CIIP
- CIPO
- congenital short bowel syndrome
- enteric neuropathy
- familial visceral myopathy
- familial visceral neuropathy
- IPO
- paralytic ileus
- pseudo-obstruction of intestine
- pseudointestinal obstruction syndrome
- pseudoobstructive syndrome

Diagnosis & Management

Genetic Testing Information

- What is genetic testing?
  /primer/testing/genetictesting
- Genetic Testing Registry: Intestinal pseudoobstruction neuronal chronic idiopathic X-linked
- Genetic Testing Registry: Natal teeth, intestinal pseudoobstruction and patent ductus
• Genetic Testing Registry: Visceral myopathy familial with external ophthalmoplegia

• Genetic Testing Registry: Visceral neuropathy familial

• Genetic Testing Registry: Visceral neuropathy, familial, autosomal dominant

Research Studies from ClinicalTrials.gov
• ClinicalTrials.gov
https://clinicaltrials.gov/ct2/results?cond=%22intestinal+pseudo-obstruction+syndrome%22+OR+%22Intestinal+Pseudo-Obstruction%22

Other Diagnosis and Management Resources
• Children's Hospital of Pittsburgh

• GeneReview: ACTG2-Related Disorders
https://www.ncbi.nlm.nih.gov/books/NBK299311

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25020006

Additional Information & Resources

Health Information from MedlinePlus
• Encyclopedia: Primary Intestinal Pseudoobstruction
https://medlineplus.gov/ency/article/000253.htm

• Health Topic: Colonic Diseases
https://medlineplus.gov/colonicdiseases.html

Genetic and Rare Diseases Information Center
• Intestinal pseudo-obstruction
https://rarediseases.info.nih.gov/diseases/6789/intestinal-pseudo-obstruction

Additional NIH Resources
• National Institute of Diabetes and Digestive and Kidney Diseases: Intestinal Pseudoobstruction
https://www.niddk.nih.gov/health-information/digestive-diseases/intestinal-pseudo-obstruction
Educational Resources

- Children's Hospital of Pittsburgh
- MalaCards: intestinal pseudo-obstruction
  https://www.malacards.org/card/intestinal_pseudo_obstruction

Patient Support and Advocacy Resources

- Association of Gastrointestinal Motility Disorders
  https://www.agmdhope.org/
- International Foundation for Functional Gastrointestinal Disorders
  https://www.iffgd.org/
- National Organization for Rare Disorders (NORD)
  https://rarediseases.org/rare-diseases/chronic-intestinal-pseudo-obstruction/

Clinical Information from GeneReviews

- ACTG2-Related Disorders
  https://www.ncbi.nlm.nih.gov/books/NBK299311

Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Intestinal+Pseudo-Obstruction%5BMAJR%5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+1080+days%22%5Bdp%5D

Catalog of Genes and Diseases from OMIM

- INTESTINAL PSEUDO-OBSTRUCTION WITH PATENT DUCTUS ARTERIOSUS AND NATAL TEETH
  http://omim.org/entry/243185
- INTESTINAL PSEUDO-OBSTRUCTION, NEURONAL, CHRONIC IDIOPATHIC, X-LINKED
  http://omim.org/entry/300048
- VISCERAL MYOPATHY, FAMILIAL, WITH EXTERNAL OPHTHALMOPEGIA
  http://omim.org/entry/277320
- VISCERAL NEUROPATHY, FAMILIAL, AUTOSOMAL DOMINANT
  http://omim.org/entry/609629
- VISCERAL NEUROPATHY, FAMILIAL, AUTOSOMAL RECESSIVE
  http://omim.org/entry/243180
Sources for This Summary


  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25020006

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22960657

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26813947
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970688/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28422808
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610062/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24676022
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967950/

Reprinted from Genetics Home Reference: 

Reviewed: December 2017 
Published: September 10, 2019 

Lister Hill National Center for Biomedical Communications 
U.S. National Library of Medicine 
National Institutes of Health 
Department of Health & Human Services